<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010516</url>
  </required_header>
  <id_info>
    <org_study_id>002</org_study_id>
    <nct_id>NCT01010516</nct_id>
  </id_info>
  <brief_title>Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia</brief_title>
  <official_title>Comparison of High-Dose Rosuvastatin Versus Low Statin Dose Plus Fenofibrate Versus Low Statin Dose Plus Niacin in the Treatment of Mixed Hyperlipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ioannina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statin therapy does not fully eliminate the cardiovascular disease (CVD) risk associated with
      low high density lipoprotein-C (HDL-C) and high triglyceride levels. It is currently unknown
      what would be the best treatment option for patients with mixed hyperlipidemia who fail to
      meet their lipid targets with statin monotherapy at conventional does, i.e. high dose
      rosuvastatin or conventional statin dose plus micronized fenofibrate or conventional statin
      dose plus niacin/laropiprant. The aim of the present study is to compare the efficacy of
      high-dose rosuvastatin vs conventional statin dose plus micronized fenofibrate vs
      conventional statin dose plus extended-release niacin/laropiprant on lipid profile in
      patients with mixed hyperlipidemia. The primary efficacy endpoint will be changes in
      non-HDL-C levels at 6 months after treatment initiation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in non-HDL-C levels</measure>
    <time_frame>6 months after treatment initiation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>High-dose rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 mg of rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stain plus fenofibrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>existing statin plus micronized fenofibrate 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Statin plus niacin ER/laropiprant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose rosuvastatin</intervention_name>
    <description>40 of rosuvastatin daily</description>
    <arm_group_label>High-dose rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin plus fenofibrate</intervention_name>
    <description>Existing statin plus micronised fenofibrate 200 mg daily</description>
    <arm_group_label>Stain plus fenofibrate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin plus niacin ER/laropiprant</intervention_name>
    <description>Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)</description>
    <arm_group_label>Statin plus niacin ER/laropiprant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-HDL-C above target goal according to NCEP-ATP III after 3 months of treatment with
             conventional statin doses, e.g. simvastatin 10-40 mg, atorvastatin 10-40 mg or
             rosuvastatin 5-20 mg

        Exclusion Criteria:

          -  Known CVD, triglycerides &gt; 500 mg/dL, renal disease (serum creatinine levels &gt; 1.6
             mg/dL), hypothyroidism [thyroid stimulating hormone (TSH) &gt; 5 IU/mL], liver disease
             (ALT and/or AST levels &gt; 3-fold upper limit of normal in more than 2 consecutive
             measurements), alcohol consumption &gt; 3 drinks/day for men and &gt; 2 drinks/day for
             women, and current or previous gout.

          -  Patients with diabetes will be included in the study if they are adequately controlled
             (HbA1c &lt;7%) with one or 2 antidiabetic drugs (no change in their treatment will be
             made during the study period).

          -  Patients with hypertension will be included in the study if they are on stable
             medication for at least 3 months and their blood pressure is adequately controlled (no
             change in their treatment will be made during the study period).

          -  Patients currently taking lipid-lowering drugs (other than statins at a conventional
             dose) or having stopped them less than 4 weeks before study entry will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moses S Elisaf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Ioannina Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moses S Elisaf, MD</last_name>
    <phone>+302651007509</phone>
    <email>egepi@cc.uoi.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Ioannina Medical School</name>
      <address>
        <city>Ioannina</city>
        <zip>45 110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M S Elisaf, MD</last_name>
      <phone>+302651007509</phone>
      <email>egepi@cc.uoi.gr</email>
    </contact>
    <investigator>
      <last_name>Moses S Elisaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evangelos N Liberopoulos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anastazia Kei, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>http://www.bpath.gr</url>
    <description>2nd Department of Internal Medicine, University Hospital of Ioannina</description>
  </link>
  <link>
    <url>http://www.uoi.gr</url>
    <description>University of Ioannina. Greece</description>
  </link>
  <link>
    <url>http://www.uhi.gr</url>
    <description>University Hospital of Ioannina, Greece</description>
  </link>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof Moses Elisaf</name_title>
    <organization>University of Ioannina Medical School</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
    <mesh_term>Hyperlipidemia, Familial Combined</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 2, 2015</submitted>
    <returned>January 6, 2016</returned>
    <submitted>July 20, 2016</submitted>
    <returned>August 31, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

